Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

The National Institute for Health and Care Excellence (NICE) invited the company that manufactures ramucirumab (Cyramza(®), Eli Lilly and Company) to submit evidence of the clinical and cost effectiveness of the drug administered alone (monotherapy) or with paclitaxel (combination therapy) for treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Büyükkaramikli, Nasuh C., Blommestein, Hedwig M., Riemsma, Rob, Armstrong, Nigel, Clay, Fiona. J., Ross, Janine, Worthy, Gill, Severens, Johan, Kleijnen, Jos, Al, Maiwenn J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5684255/
https://www.ncbi.nlm.nih.gov/pubmed/28656543
http://dx.doi.org/10.1007/s40273-017-0528-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5684255/
https://www.ncbi.nlm.nih.gov/pubmed/28656543
http://dx.doi.org/10.1007/s40273-017-0528-y

Ejemplares similares